Abbott Laboratories (ABT): Capital Expenditures
$2.17B
Year ended 2025-12-31
$2.09B
Trailing 12 months to 2026-03-31
+6.9%
3-year compound annual growth
-0.1%
5-year compound annual growth
+6.9%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.17B | -1.6% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $2.21B | +0.2% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $2.20B | +23.9% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $1.78B | -5.7% | 2025-02-21, From 2022-01-01 |
| 2021-12-31 | $1.89B | -13.4% | 2024-02-16, From 2021-01-01 |
| 2020-12-31 | $2.18B | +32.9% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $1.64B | +17.5% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $1.39B | +22.8% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $1.14B | +1.2% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $1.12B | +1.0% | 2019-02-22, From 2016-01-01 |
| 2015-12-31 | $1.11B | +3.1% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $1.08B | -5.9% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $1.15B | -36.2% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $1.79B | +20.4% | 2015-02-27, From 2012-01-01 |
| 2011-12-31 | $1.49B | +46.9% | 2014-02-21, From 2011-01-01 |
| 2010-12-31 | $1.02B | -6.8% | 2013-02-15, From 2010-01-01 |
| 2009-12-31 | $1.09B | -15.4% | 2012-02-21, From 2009-01-01 |
| 2008-12-31 | $1.29B | -22.2% | 2011-02-18, From 2008-01-01 |
| 2007-12-31 | $1.66B | n/a | 2010-02-19, From 2007-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Abbott Laboratories (ABT) | 2025-12-31 | $2.17B | -1.6% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $1.31B | +5.0% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $1.21B | +24.6% |
| Pfizer Inc (PFE) | 2025-12-31 | $2.63B | -9.6% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $4.11B | +21.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $4.83B | +9.2% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $501.00M | +0.6% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $898.40M | +18.9% |
| Viatris Inc (VTRS) | 2025-12-31 | $378.80M | +16.2% |
Compare ABT, BMY, ABBV, PFE side by side · Screen every company in Pharmaceutical Preparations ↗